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Background: It has been previously reported that oral administration of sodium pyruvate 
inhibits oxidative stress and cataract formation in diabetic animals. With a view to exploring the 
clinical usefulness of these findings, this study examined its preventive effect when administered 
topically as an eye drop.
Methods: Diabetes was induced by intraperitoneal injections of streptozotocin. At the onset 
of diabetes, an eye drop preparation containing 2.5% sodium pyruvate was administered six 
times a day at 90-minute intervals. Treatment was continued for 6 weeks. Cataract formation 
was monitored ophthalmoscopically after mydriasis with 1% tropicamide eye drops. Subse-
quently, the treated and untreated diabetic animals and the age-matched normal controls were 
euthanized, their eyes enucleated, and the lenses isolated for biochemical assessment of protein 
glycation and glutathione levels.
Results: Treatment with pyruvate eye drops was found to be significantly effective in inhibiting 
protein glycation. Glutathione levels were also better maintained. In addition, ophthalmoscopic 
examination revealed that the incidence of cataract in the pyruvate-treated group was only 12% 
as compared with the untreated diabetics in whom the incidence was 73%. Cataracts at this 
stage were largely equatorial.
Conclusion: The results demonstrate that topical application of pyruvate can potentially be 
useful in attenuating or preventing cataract formation induced by diabetes and other conditions 
of oxidative stress.
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Introduction
Cataract is one of the most common causes of vision impairment and blindness 
with significant adverse effects on the quality of life of the individual.1 Even though 
surgical treatment is successful in restoring vision, the incidence of this disease is 
so high that surgery alone has not been able to eradicate cataract blindness, mainly 
because of replacement of old cases with new ones as well as the increase in longevity. 
Therefore, it is highly desirable to explore the possibility of preventing or treating 
cataracts pharmacologically.
Several previous studies strongly suggest that oxidative stress consequent to exces-
sive generation of oxygen free radicals is one of the significant factors involved in 
the pathogenesis of this aging disease.2–5 This is attributable to decreased activity of 
endogenous antioxidant defense enzymes, viz., catalase, superoxide dismutase, and 
glutathione peroxidase, as well as accumulation of tryptophan degradation products, 
such as kynurenine. The latter can induce oxidative stress by acting as a photosensitizer Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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and consequently generate excessive reactive oxygen species 
during photopic vision.6,7 The consequent increase in reactive 
oxygen species leads to oxidative modifications of cellular 
constituents, such as the enzymatic and nonenzymatic pro-
teins, lipids, nucleic acids, and the pyridine nucleotides, with 
deleterious effects. Reactive oxygen species generation is 
further enhanced in certain diseases such as diabetes, wherein 
the cataract is known to start at an earlier age and progresses 
relatively faster than in nondiabetics.8–10 Enhancement of the 
process in diabetes has been attributed to increased generation 
of reactive oxygen species by metal-catalyzed auto-oxidation 
of glucose present at higher concentrations. In addition to 
increased reactive oxygen species generation, the process is 
accompanied by generation of highly reactive dicarbonyls11–13 
which modify protein structures and functions by glycation, 
leading eventually to formation of advanced glycation end-
products and the high molecular weight protein aggregates 
characteristic of cataracts. Glycated proteins can by them-
selves generate oxyradical species, thereby perpetuating the 
oxidative stress even further. The reactive oxygen species 
generated are known to be highly effective in causing −SH 
oxidation of several enzymes involved in the maintenance of 
tissue physiology, such as glyceraldehyde-3-phosphate dehy-
drogenase, a key glycolytic enzyme. Metabolic inhibition in 
diabetes is reflected also by a decreased respiratory quotient, 
ie, CO2/O2, first demonstrated by Richardson and Levine,14 
showing decreased utilization of molecular oxygen through 
normal metabolic pathways and its consequent diversion to 
auto-oxidation reactions known to proceed monovalently. 
In addition to its adverse effects on metabolic enzymes, 
reactive oxygen species inhibit membrane transport activity 
by inactivating Na+-K+ ATPase,15,16 the enzyme responsible 
for maintaining the lens in a deturgesced state by regulating 
active transport of cations. Hence the deleterious effects of 
reactive oxygen species are varied in nature. Therefore, it is 
expected that the use of reactive oxygen species scavengers 
would be beneficial in preventing oxidative stress-induced 
damage to the lens and cataract formation.
Previous studies, including those from our laboratory, 
have shown that nutritional antioxidants, such as ascorbate 
and   vitamin E, are effective in preventing cataract formation 
in animal models of  oxidative stress as well as diabetes.17,18 
However, the clinical usefulness of these compounds becomes 
limited due to their tendency to become pro-oxidant following 
their reaction with reactive oxygen species.19 Therefore, we 
believe that the effectiveness of such scavengers could be 
enhanced if they are able to provide bioenergetic support to 
the tissue simultaneously by facilitating ATP generation. In 
this regard, we have previously shown that pyruvate is highly 
effective in preventing oxidative stress to the lens in vitro,16 as 
well as in preventing actual cataract formation in vivo when 
administered orally to rats or mice with experimentally-induced 
diabetes.20,21 The latter is the preferred model for such studies 
due to its low aldose reductase activity in the lens, similar to 
that in the human lens.22 The ability of pyruvate in preventing 
cataract formation is also reflected biochemically in terms of 
the maintenance of levels of glutathione and inhibition of pro-
tein glycation in the lenses of diabetic mice. Its beneficial effect 
was further apparent in terms of prevention of diabetes-induced 
apoptotic changes in the lens.23 Encouraged by these findings, 
we undertook the present investigation to examine the possibil-
ity of inhibiting diabetic cataract formation by topical treatment 
with pyruvate eye drops, a pharmacologically more acceptable 
and often more effective way of treating eye diseases.
Materials and methods
CD-1 mice (body weight 25 g) obtained from Charles River 
Laboratories (Wilmington, MA) were used in this research. The 
procedures used for animal handling and euthanasia followed 
the Association for Research in Vision and   Ophthalmology 
  Statement for the Use of Animals in Research and were approved 
by the Institutional Animal Care and Use   Committee.   Diabetes 
was induced by intraperitoneal injection of   streptozotocin 
40 mg/kg body weight for five consecutive days. Onset of hyper-
glycemia was ascertained one week following streptozotocin by 
determining the levels of blood glucose with a glucometer using 
tail blood. Animals with blood glucose of 350–400 mg/dL were 
included in the study. The diabetic animals were divided into two 
groups whereby one group was left untreated (control diabetics) 
and the second group was treated with 2.5% sodium pyruvate 
eye drops six times a day, the treatment being started imme-
diately following the establishment of diabetes and continued 
until 6 weeks. The eye drops were freshly prepared daily by 
dissolving 2.5 g sodium pyruvate in a solution containing 0.3% 
hydroxypropyl methyl cellulose (3500–5600 cps, pH about 7) 
as a wetting agent. Development of cataract was monitored by 
ophthalmoscopy following mydriasis with 1% tropicamide eye 
drops. After six weeks of treatment, the untreated and treated 
diabetic animals as well as the age-matched normal controls 
were euthanized, their eyes enucleated, and the lenses isolated 
for biochemical analyses.
Penetration of sodium pyruvate  
in aqueous humor
That the pyruvate administered topically does penetrate 
through the cornea was ascertained by determining its Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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level in the aqueous humor following instillation in normal 
mice before the start of the actual studies. This was done 
as follows. After induction of anesthesia by intraperitoneal 
ketamine:xylazine (80 mg/kg body weight ketamine, 
10 mg/kg body weight xylazine), about 25 µL of the above 
eye drop preparation was administered in the cul-de-sac of the 
mouse eye. At 30 minutes after administering the eye drops, 
the eye was rinsed with normal saline and aqueous humor 
aspirated using a 25 G 5/8 disposable needle attached to an 
insulin syringe and analyzed for its pyruvate content. The 
basal level of pyruvate in the aqueous humor was determined 
in the anesthetized animals that did not receive the eye drops. 
Pyruvate concentration was determined enzymatically by 
mixing the sample with nicotinamide adenine dinucleotide 
and lactate dehydrogenase reagent and monitoring spectro-
photometrically the decrease in absorption (at 340 nm) due to 
reduction of pyruvate to lactate, as reported previously.24
Biochemical analyses of the lenses obtained from 
normal, untreated, and pyruvate-treated diabetic groups 
were done as follows: An aqueous extract of the tissue was 
prepared by homogenization in 0.5 mL distilled H2O and 
centrifugation at 14,000 rpm. The supernatant was used for 
determining glutathione and glycated protein content. 
Determination of lens glutathione 
content
Glutathione was determined in an aliquot of the above 
supernatant using Ellman’s reaction.25 After precipitating the 
proteins present therein by addition of trichloroacetic acid 
to a final concentration of 5%, the sample was centrifuged. 
About 100 µL of the supernatant so obtained was reacted with 
100 µL of Ellman’s reagent after neutralization with 300 µL 
of 0.6 M Na2HPO4. The yellow color developed due to the 
formation of thionitrobenzoate was then read at 412 nm.
Measurement of protein glycation
Protein glycation was measured as follows.20,21 The content of 
water-soluble proteins in the   aqueous supernatant prepared 
as described earlier was determined by Bradford’s method 
using BioRad protein reagent. An aliquot of the supernatant 
containing 100 µg of the proteins was then loaded on a bor-
onate affinity chromatographic column (Sigma kit 442-B; 
Sigma-Aldrich, St Louis, MO) which binds glycated proteins 
containing cis-diols of the sugar bound to the protein. After 
10 minutes of reaction on the column, the unglycated proteins 
were eluted with phosphate buffer pH 9 (Sigma 442-3). The 
glycated protein was then eluted with 50 mM sorbitol in 0.4 N 
NaOH. Total proteins were determined in the two fractions 
by Bradford’s method, and the percentage of glycated protein 
was calculated.
Results
Previous studies from our laboratory have demonstrated the 
effectiveness of pyruvate in preventing cataract formation 
in diabetic animals. The preventive effect was evaluated 
biochemically as well as morphologically. Pyruvate was 
administered systemically by mixing it in the diet. However, 
given that topical treatment is the preferred mode of treatment 
for ocular diseases, it was considered desirable to determine 
the efficacy of topical instillation of pyruvate. Therefore, 
initial experiments were done to examine if adequate levels 
of the compound in the aqueous humor are indeed attained 
following such treatment. The level of pyruvate in the 
aqueous increases from a basal level of about 0.2 mM to about 
1.2 mM at 30 minutes following instillation of 2.5% sodium 
pyruvate eye drops in the normal mouse eye. It decreases to 
the basal level by 60 minutes. Instillation of such an eye drop 
preparation in the mouse eye six times daily was found to be 
highly effective in inhibiting the onset of cataract formation. 
The earliest sign of cataract in diabetic mice consisted of the 
appearance of a peripheral ring of cloudiness in the lens, 
visible ophthalmoscopically at about 5–6 weeks of diabetes. 
However, such opacity was difficult to discern by standard 
slit lamp examination due to the convexity of the lens and 
peripheral location of the opacity. As shown in Table 1, 
73% of the eyes in the untreated diabetic group had such 
cataracts. Interestingly, in the diabetic animals receiving 
pyruvate eye drops, only 12.5% of the eyes had developed 
early cataractous changes.
Inhibition of cataract formation by topical pyruvate 
treatment was due to inhibition of oxidative stress, as 
indicated by measurements of glutathione levels. As shown 
in Figure 1, the level of glutathione, the primary antioxidant 
reserve of the tissue, decreased significantly (by about 
50%) in the diabetic mouse lens to about 1.2 µmol/g from 
a normal value of approximately 2.4 µmol/g. Pyruvate 
administration prevented this decrease, the levels in this 
case being approximately 2.3 µmol/g, which is close to the 
normal. In addition to the direct effect of reactive oxygen 
species on glutathione, an additional mechanism by which 
glucose induces lens opacity is structural modification of 
the lens proteins by nonenzymatic glycation and subsequent 
formation of advanced glycation end-products and high 
molecular weight aggregates with decreased solubility. As 
shown in Figure 2, the level of glycated proteins in the normal 
lens was about 1.5%, which increased to nearly 9% in the Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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diabetic lens. Treatment with pyruvate eye drops substantially 
prevented such an increase, the level in this case being only 
about 3%.
Discussion
Diabetes is one of the significant risk factors for development 
of cataract. This is apparent in several studies showing that 
the incidence of cataracts in the diabetic population is higher 
than in nondiabetics. In addition, the onset of cataract occurs 
at an earlier age and progresses at a faster pace in diabetics. 
One of the important factors involved in the pathogenesis 
of cataracts is induction of oxidative stress consequent to 
excessive intraocular generation of reactive oxygen species 
triggered by the high levels of glucose in the extracellular 
as well as intracellular fluids. The latter is especially true 
in relatively insulin-insensitive tissues such as the lens. We 
have previously shown that such stress induced in the lens 
by diabetes is preventable by oral administration of pyruvate, 
a potent oxyradical scavenger and a metabolic agonist. The 
anticataractogenic effect of systemic treatment with pyru-
vate encouraged us to undertake further studies examining 
its potential effectiveness against cataract development by 
topical administration, which is the preferred route for such 
treatment clinically. It is expected that a higher level of the 
compound can be achieved in the aqueous humor when it is 
administered by this route. Indeed adequate levels of pyruvate 
were attained in the aqueous humor (about 1.2 mM) following 
its topical instillation. We have recently shown that it also 
penetrates the human cornea to a significant extent when 
administered topically.26 The levels so attained in the aqueous 
humor were found to be significantly effective in inhibiting 
oxidative stress at the lens, apparent by the maintenance of 
glutathione levels. This effect is attributable primarily to the 
ability of pyruvate to scavenge reactive oxygen species. The 
reaction of pyruvate with all such species has been shown to 
be thermodynamically highly favorable, including its reaction 
with the hydroxyl radical.27,28
Pyruvate treatment was also effective in inhibiting protein 
glycation. It has previously been shown to exert this effect 
through competitive inhibition of glycation by glucose. 
The carbonyl group of pyruvate competes with the glucose 
carbonyl for reaction with the −NH2 protein group for the 
formation of the initial Schiff’s adduct. Because the carbonyl 
group of glucose and its derivatives remains masked in the 
hemiacetal configuration, it is less freely available for reacting 
with the −NH2 protein versus the pyruvate carbonyl which is 
exposed to react. In addition, due to the absence of vicinyl 
hydroxyl groups in the Schiff’s base formed between −NH2 
Table 1 effect of pyruvate eye drops on the development of cataract in diabetic mice was assessed by ophthalmoscopy after mydriasis. 
As shown, the number of cataracts in the untreated diabetic group was significantly higher as compared with the pyruvate-treated 
group. Duration of diabetes was 6 weeks
Normal Diabetes (6 weeks) Diabetes (6 weeks) +  
2.5% pyruvate eye drops
eyes with cataract (n) 0/12 eyes 16/22 eyes (73%) 3/24 eyes (12.5%)
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Figure  1  Levels  of  glutathione  in  the  diabetic  mouse  lens.  glutathione  was 
determined in the acid extract of the tissue as described in the text to estimate the 
effect of topical pyruvate. 
Note: Data represent mean ± standard deviation (n = 6; P , 0.001) between normal 
and untreated diabetic groups as well as between the untreated and pyruvate-
treated diabetic groups.
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Figure 2 effect of pyruvate eye drops on the extent of protein glycation in the 
diabetic mouse lens: glycated proteins were determined in the aqueous lens extract 
by affinity chromatography using a boronate column. 
Note: results represent mean ± standard deviation (n = 6, P , 0.001) between 
normal and untreated diabetic groups as well as between untreated and pyruvate-
treated diabetic groups.Clinical Ophthalmology
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protein and pyruvate, the complex does not undergo Amadori 
rearrangement and hence formation of advanced glycation 
end-products is prevented.
The protective effect of pyruvate eye drops against 
biochemical damage to the lens in diabetic animals was 
hence similar to that observed with its oral administration. 
We believe that the effectiveness of topical pyruvate can be 
further enhanced by using its ester, ethyl pyruvate, shown 
recently by us to attain significantly higher concentrations 
than its sodium salt in the aqueous humor and lens.24 Further 
studies examining its effectiveness in preventing cataract 
formation in diabetic animals even until later stages of the 
disease are in progress.
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